Sukriti Vishwas

Dr. Sukriti Vishwas

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LCLeander Corrie
Leander Corrie
AAAnkit Awasthi
Ankit Awasthi
JKJaskiran Kaur
Jaskiran Kaur
SVSukriti Vishwas
Sukriti Vishwas
DGDr. Monica Gulati
Dr. Monica Gulati
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
Polycystic Ovarian Syndrome (PCOS) comprises a set of symptoms that pose significant risk factors for various diseases, including type 2 diabetes, cardiovascular disease, and cancer. Effective and safe methods to treat all the pathological symptoms of PCOS are not available. The gut microbiota has been shown to play an essential role in PCOS incidence and progression. Many dietary plants, prebiotics, and probiotics have been reported to ameliorate PCOS. Gut microbiota shows its effects in PCOS via a number of mechanistic pathways including maintenance of homeostasis, regulation of lipid and blood glucose levels. The effect of gut microbiota on PCOS has been widely reported in animal models but there are only a few reports of human studies. Increasing the diversity of gut microbiota, and up-regulating PCOS ameliorating gut microbiota are some of the ways through which prebiotics, probiotics, and polyphenols work. We present a comprehensive review on polyphenols from natural origin, probiotics, and fecal microbiota therapy that may be used to treat PCOS by modifying the gut microbiota.

1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AAAnkit Awasthi
Ankit Awasthi
DGDr. Monica Gulati
Dr. Monica Gulati
BKBIMLESH KUMAR
BIMLESH KUMAR
JKJaskiran Kaur
Jaskiran Kaur
SVSukriti Vishwas
Sukriti Vishwas
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
Diabetic wound (DW) is a secondary application of uncontrolled diabetes and affects about 42.2% of diabetics. If the disease is left untreated/uncontrolled, then it may further lead to amputation of organs. In recent years, huge research has been done in the area of wound dressing to have a better maintenance of DW. These include gauze, films, foams or, hydrocolloid‐based dressings as well as polysaccharide‐ and polymer‐based dressings. In recent years, scaffolds have played major role as biomaterial for wound dressing due to its tissue regeneration properties as well as fluid absorption capacity. These are three‐dimensional polymeric structures formed from polymers that help in tissue rejuvenation. These offer a large surface area to volume ratio to allow cell adhesion and exudate absorbing capacity and antibacterial properties. They also offer a better retention as well as sustained release of drugs that are directly impregnated to the scaffolds or the ones that are loaded in nanocarriers that are impregnated onto scaffolds. The present review comprehensively describes the pathogenesis of DW, various dressings that are used so far for DW, the limitation of currently used wound dressings, role of scaffolds in topical delivery of drugs, materials used for scaffold fabrication, and application of various polymer‐based scaffolds for treating DW.

5 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DJDeeksha Joshi
Deeksha Joshi
RKRubiya Khursheed
Rubiya Khursheed
SGSaurabh Gupta
Saurabh Gupta
DWDiksha Wadhwa
Diksha Wadhwa
TSThakur Gurjeet Singh
Thakur Gurjeet Singh
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
Biologic-based medicines are used to treat a variety of diseases and account for around one-quarter of the worldwide pharmaceutical market. The use of biologic medications among cancer patients has resulted in substantial advancements in cancer treatment and supportive care. Biosimilar medications (or biosimilars) are very similar to the reference biologic drugs, although they are not identical. As patent protection for some of the most extensively used biologics begins to expire, biosimilars have the potential to enhance access and provide lower-cost options for cancer treatment. Initially, regulatory guidelines were set up in Europe in 2003, and the first biosimilar was approved in 2006 in Europe. Many countries, including the United States of America (USA), Canada, and Japan, have adopted Europe’s worldwide regulatory framework. The use of numerous biosimilars in the treatment and supportive care of cancer has been approved and, indeed, the count is set to climb in the future around the world. However, there are many challenges associated with biosimilars, such as cost, immunogenicity, lack of awareness, extrapolation of indications, and interchangeability. The purpose of this review is to provide an insight into biosimilars, which include various options available for oncology, and the associated adverse events. We compare the regulatory guidelines for biosimilars across the world, and also present the latest trends and challenges in medical oncology both now and in the future, which will assist healthcare professionals, payers, and patients in making informed decisions, increasing the acceptance of biosimilars in clinical practice, increasing accessibility, and speeding up the health and economic benefits associated with biosimilars.

5 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MTMahesh Hanmantrao Tidke
Mahesh Hanmantrao Tidke
SCSourabh Chaterjee
Sourabh Chaterjee
RKRajan Kumar
Rajan Kumar
SVSukriti Vishwas
Sukriti Vishwas
VHVancha Harish
Vancha Harish
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
Present study deciphers development of oral polysaccharide-based colon targeted solid self-nanoemulsifying drug delivery system (S-SNEDDS) of xanthohumol (XH). Several studies have shown that XH has anti-inflammatory and antioxidant properties, suggesting that it could be a good candidate for the treatment of colorectal diseases (CRD). Despite its potential, XH has a low aqueous solubility. As a result, its bioavailability is constrained by the dissolution rate. The liquid (L)-SNEDDS was constituted using Labrafac PG as oil, Tween 80 as surfactant and Transcutol P as co-surfactant. The L-SNEDDS was then adsorbed onto the surface of guar gum and pectin and developed into S-SNEDDS powder. Ternary phase diagram was used to optimize the process of developing L-SNEDDS. The formulation showed mean droplet size of 118.96 ± 5.94 nm and zeta potential of −19.08 ± 0.95 mV and drug loading of 94.20 ± 4.71%. Dissolution studies carried out in medium containing rat caecal contents (RCC) represented the targeted release of S-SNEDDS powder. It was observed that S-SNEDDS showed less than 10% release XH in initial 5 h and rapid release occurred between the 5th and 10th hour. Results of cytotoxicity studies revealed good cytotoxicity of XH loaded S-SNEDDS for Caco2 cells as compared to raw-XH.

25 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Keshav Raj PaudelKeshav Raj Paudel
Keshav Raj Paudel
Saurav Kumar JhaSaurav Kumar Jha
Saurav Kumar Jha
VAVenkata Sita Rama Raju Allam
Venkata Sita Rama Raju Allam
Parteek PrasherParteek Prasher
Parteek Prasher
Piyush Kumar GuptaPiyush Kumar Gupta
Piyush Kumar Gupta
Kamal DuaKamal Dua
Kamal Dua
Respiratory diseases contribute to a significant percentage of mortality and morbidity worldwide. The circadian rhythm is a natural biological process where our bodily functions align with the 24 h oscillation (sleep–wake cycle) process and are controlled by the circadian clock protein/gene. Disruption of the circadian rhythm could alter normal lung function. Chronotherapy is a type of therapy provided at specific time intervals based on an individual’s circadian rhythm. This would allow the drug to show optimum action, and thereby modulate its pharmacokinetics to lessen unwanted or unintended effects. In this review, we deliberated on the recent advances employed in chrono-targeted therapeutics for chronic respiratory diseases.

6 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LCLeander Corrie
Leander Corrie
JKJaskiran Kaur
Jaskiran Kaur
AAAnkit Awasthi
Ankit Awasthi
SVSukriti Vishwas
Sukriti Vishwas
DGDr. Monica Gulati
Dr. Monica Gulati
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
The study was initiated with two major purposes: investigating the role of isomalt (GIQ9) as a pharmaceutical carrier for solid self-nanoemulsifying drug delivery systems (S-SNEDDSs) and improving the oral bioavailability of lipophilic curcumin (CUN). GIQ9 has never been explored for solidification of liquid lipid-based nanoparticles such as a liquid isotropic mixture of a SNEDDS containing oil, surfactant and co-surfactant. The suitability of GIQ9 as a carrier was assessed by calculating the loading factor, flow and micromeritic properties. The S-SNEDDSs were prepared by surface adsorption technique. The formulation variables were optimized using central composite design (CCD). The optimized S-SNEDDS was evaluated for differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), microscopy, dissolution and pharmacokinetic studies. The S-SNEDDS showed a particle size, zeta potential and PDI of 97 nm, −26.8 mV and 0.354, respectively. The results of DSC, XRD, FTIR and microscopic studies revealed that the isotropic mixture was adsorbed onto the solid carrier. The L-SNEDDS and S-SNEDDS showed no significant difference in drug release, indicating no change upon solidification. The optimized S-SNEDDS showed 5.1-fold and 61.7-fold enhancement in dissolution rate and oral bioavailability as compared to the naïve curcumin. The overall outcomes of the study indicated the suitability of GIQ9 as a solid carrier for SNEDDSs.